- Previous Close
103.92 - Open
104.22 - Bid 106.57 x 800
- Ask 107.26 x 900
- Day's Range
103.56 - 107.31 - 52 Week Range
89.67 - 121.64 - Volume
8,673,501 - Avg. Volume
6,063,727 - Market Cap (intraday)
186.593B - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
33.84 - EPS (TTM)
3.17 - Earnings Date Oct 16, 2024 - Oct 21, 2024
- Forward Dividend & Yield 2.20 (2.05%)
- Ex-Dividend Date Jul 15, 2024
- 1y Target Est
114.49
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
www.abbott.comRecent News: ABT
View More
Related Videos: ABT
Performance Overview: ABT
Trailing total returns as of 7/24/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABT
View MoreValuation Measures
Market Cap
186.59B
Enterprise Value
194.53B
Trailing P/E
33.84
Forward P/E
22.99
PEG Ratio (5yr expected)
4.34
Price/Sales (ttm)
4.61
Price/Book (mrq)
4.81
Enterprise Value/Revenue
4.78
Enterprise Value/EBITDA
21.92
Financial Highlights
Profitability and Income Statement
Profit Margin
13.65%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
40.73B
Net Income Avi to Common (ttm)
5.54B
Diluted EPS (ttm)
3.17
Balance Sheet and Cash Flow
Total Cash (mrq)
6.65B
Total Debt/Equity (mrq)
37.66%
Levered Free Cash Flow (ttm)
--
Research Analysis: ABT
View MoreCompany Insights: ABT
ABT does not have Company Insights
Research Reports: ABT
View MoreMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, Grab Holdings worth grabbing now; examining medical-device makers' moat; a hard look at software makers' moat; and Vesync, Macy's, and Travelers Companies.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, Grab Holdings worth grabbing now; examining medical-device makers' moat; a hard look at software makers' moat; and Vesync, Macy's, and Travelers Companies.
The Argus Min Vol Model Portfolio
Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.
The Argus Min Vol Model Portfolio
Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.